Strychnine-sensitive glycine receptors are expressed in many adult forebrain regions, yet the biological function of these receptors outside the spinal cord/brainstem is poorly understood. We have recently shown that rat lateral/basolateral amygdala neurons express strychnine-sensitive glycine-gated currents whose pharmacological and molecular characteristics are consistent with those established for classic ligand-gated chloride channels. The current studies were undertaken to establish the behavioral role, if any, of these strychnine-sensitive glycine receptors. Adult LongEvans male rats were implanted with guide cannulae targeted at the lateral amygdala and were microinjected with standard artificial cerebrospinal fluid with or without various doses of strychnine or taurine. Anxiety-like behaviors were assessed with the elevated plus maze or the light/dark box. In the elevated plus maze, strychnine decreased closed-arm time and increased open-arm time, suggestive of an anxiolytic effect. Similarly, strychnine produced a modest anxiolytic effect in the light/dark box. Post hoc analysis of 'open-arm' time and 'light-side' time indicated that aCSFtreated animals were distributed into two apparent groups that displayed either high or low amounts of anxiety-like behavior in a given apparatus. Surprisingly, the pharmacological effects of both strychnine and taurine in these assays were dependent upon a given animal's behavioral phenotype. Together, these findings are significant because they suggest that the basal 'emotional state' of the animal could influence the behavioral outcome associated with drug application directly into the lateral/basolateral amygdala. Furthermore, our findings also suggest that compounds acting at amygdala strychnine-sensitive glycine receptors may actively modulate this basal anxiety-like state.
Introduction
The amygdala plays a central role in determining the emotional valence of environmental stimuli. To accomplish this, it receives processed sensory information from thalamus and primary somato-sensory cortex, processes this information, and sends projections to brain regions involved with assessing the reward (N. accumbens; [20] ) and risks (prefrontal cortex; [17] ) associated with the environment. In addition to these more cognitive responses, the amygdala also sends projections to brain areas that regulate an organism's physical response to environmental stimuli [28] . While this complex functional contribution is necessarily governed by several anatomically, functionally, and morphologically distinct subdivisions, the lateral and basolateral nuclei are known to be centrally important for this integrative process and are the primary input nuclei of this brain area. These subdivisions subsequently regulate the expression of innate anxiety-like behaviors [1] as well as more complex associational learning related to emotionally relevant cues like painful or fear-evoking stimuli [13, 18, 26, 43] . More recent findings have demonstrated that the lateral/basolateral subdivision also mediates behaviors relevant for drugs of abuse [14, 46] . The neurophysiological mechanisms modulating these complex and highly integrative functions are just beginning to be understood. As in many brain regions, the balance between excitatory and inhibitory neurotransmitter systems appears to play an important role in these processes.
Strychnine-sensitive glycine receptors (ssGlyRs) are ligandgated chloride channels. Like GABA A receptors, each channel is composed of a complex of five distinct transmembrane-spanning proteins [22] that confer specific biophysical and pharmacological properties to the receptor complex. These subunits are derived from two distinct gene families, the ␣ and ␤ subunits [21] . The ␣ subunit can form functional homomeric channels and can arise from four different gene products (denoted ␣ 1-4 , reviewed in [8] ). However, the presence of the ␤ subunit can confer pharmacological properties that are more consistent with native receptors [19, 39] . As its name implies, these chloride-permeant glycine receptors bind the plant alkaloid strychnine with high affinity and are robustly inhibited by this competitive antagonist. This exquisite sensitivity to strychnine distinguishes these channels pharmacologically from the glycine site associated with the N-methyl-d-aspartate family of glutamate receptors. In addition, ssGlyRs can be gated by the ␤-amino acids, including ␤-alanine and taurine, which act as partial agonists [45] . Like glycine, taurine and ␤-alanine are abundant in the central nervous system and could also serve as native agonists for ssGlyRs in some brain regions [34] .
In the context of the current study, functional ssGlyR are expressed in adult rat amygdala. When measured in acutely isolated lateral/basolateral amygdala neurons, ssGlyRs possess pharmacological and biophysical characteristics that are consistent with the classical ligand-gated chloride channel [29] . These amygdala ssGlyRs are activated by glycine, ␤-alanine, and taurine with the latter ␤-amino acids acting as almost full (␤-alanine) or relatively weak (taurine) partial agonists. The amygdala ssGlyRs are also sensitive to low concentrations of strychnine and are completely inhibited by concentrations <1 M [29] . Amygdala glycine receptors are also relatively insensitive to non-competitive antagonist picrotoxin [30] , and these findings indicate that amygdala ssGlyRs are likely to heteromeric assemblies containing the ␤-subunit [39] . These receptors are expressed by both the principal glutamatergic projection neurons as well as some population of GABAergic interneurons and consist primarily of the ␣ 2 subunit-containing channels although mRNAs for ␣ 1 and ␣ 3 are also found in some cells [30] . Exogenous glycine application to amygdala in vitro slice preparations produces strychnine-sensitive membrane hyperpolarizations [12] . Since amygdala ssGlyR expression is conserved across several species including humans [16] and nonhuman primates (McCool, unpublished observations), these in vitro findings may indicate a highly conserved role for amygdala ssGlyRs.
Despite mounting evidence that ssGlyRs expressed in the adult forebrain can robustly regulate neural function, there are no studies demonstrating a functional role for these receptors in vivo. With this in mind, the current study examines the anxiety-related consequences of strychnine and taurine microinjection into rat lateral/basolateral amygdala. We have chosen to quantify anxiety-like behavior with two independent assays, the light/dark box and the elevated plus maze. Both assays provide measures of unconditioned avoidance of naturally aversive environments (i.e. the light side of the light/dark box or the open arms of the elevated plus maze); and, behaviors expressed in these assays frequently display a similar pharmacological sensitivity to anxiolytic compounds. However, the two tests appear to assay unique cognitive and genetic contributions to the expression of anxiety [10, 11] . The current experiments will utilize these unique qualities to test the hypothesis that strychnine-sensitive glycine receptors help to modulate amygdala-dependent behaviors.
Materials and methods

Animals
Adult male Long-Evans rats (250-275 g) obtained from Harlan, Indianapolis, IN, were used in this study. All rats were individually housed in hanging stainless steel cages with food and water available ad libitum. Artificial lighting was on for 12 h/day, starting at 06:00 h. The animals were kept in an AAALAC approved animal facility, with temperature maintained in accordance with NIH Animal Guidelines. All experimental procedures were approved by the Wake Forest University School of Medicine Animal Care and Use Committee.
Surgical procedure
When each individual weighted between 300-310 g, rats were anesthetized with sodium pentobarbital (50 mg/kg, IP) and were placed into a rodent stereotaxic instrument (model 962, Kopf Instruments, Tujunga, CA) with the incisor bar set at 3.3 mm below the interaural line. After a midline incision was made over the skull, the skull was scraped clean, four holes were then drilled into the skull and self-tapping stainless-steel screws were inserted to help anchor the guide cannulae. Next, two additional sites were drilled, and stainless steel guide cannulae (26 gauge) of sufficient length were implanted to terminate 1 mm above the basolateral amygdala, typically within the lateral nucleus. The coordinates of our target site were: antero-posterior, −2.80 mm from bregma; medio-lateral, from the midline +5.05 mm; ventral from the top of the brain, −6.20 mm [36] . Dental cement (Lang Dental, Wheeling, IL) was used to affix the guide cannulae and to stabilize the assembly by adhering to the four stainless steel screws. Obturators were used to maintain the patency of the guide cannulae. Following the surgical procedures, each rat had 5 days of recovery during which time they were extensively handled by the same experimentor who performed the microinjections.
Microinjection procedure
Beginning on the sixth day following surgery, each rat was placed in a small holding tub (27 cm × 17 cm × 12 cm) for 4 min on 5 consecutive days. During this time, the rats were gently restrained by hand, obturators were removed, and an electric pump was turned on. Following this, clean, sterile obturators were placed back into the guide cannulae. Animals were then placed into a transport cage before being placed back into the home cage. These procedures were performed to habituate rats to the handling and noises associated with the microinjection procedure.
On experimental days, the obturators were removed and 33 gauge injector-cannulae were inserted into the guide cannulae. The injectors were of sufficient length to extend 1 mm beyond the end of the guide cannulae. Drug solutions were bilaterally infused for 1 min with 0.5 l total volume delivered per side. Injectors were left in place for 30 s after the end of the infusion and then clean, sterile obturators were inserted back into the guide cannulae. Rats were placed into a transport cage and moved into an adjacent testing room for 10 min before entering the behavioral apparatus. This time was deemed long enough to allow animals to become accustomed to the testing environment yet short enough to insure that drug-effects were still present during the testing [42] .
Apparatus
To assess the effects of drug delivery into the basolateral amygdala, two different assays were employed to assess anxiety-like behaviors. Sessions were performed using the elevated plus maze [37] To measure anxiety with the light/dark box [31] , individuals were placed in the 'light' side of a 40 cm × 40 cm plexiglass arena divided equally into 'light' and 'dark' sides by an opaque plexiglass insert (Rat Truscan Activity Arena, Coulbourn Instruments, Allentown, PA) illuminated by ambient room lighting to ∼400 lx at the center of the 'light' side. The geometric center of the animal ±1.3 cm was followed for 5 min by two infrared senor rings surrounding the entire apparatus, one in the floor plane and one located ∼15 cm above the floor to measure rearing behavior. Data were collected at 0.25 Hz and stored on a personal computer. Dependent variables included total distance moved, total number of moves, total time spent moving, time to leave the light side following initial placement, time to return to the light side after initial entry to the dark side, total time spent in the light and dark compartments, number of light-dark transitions, and number of vertical beam breaks. Between animals, the apparatus was cleaned with warm water, 70% ethanol, again with warm water, and thoroughly dried.
Experimental design
Animals were randomly assigned to different treatment groups and were bilaterally microinjected with standard artificial cerebrospinal fluid (aCSF) with or without various doses of strychnine or taurine. Each week, animals were exposed to a single injection followed by testing in a single apparatus. To reduce the 'one-trial tolerance' effect [4] in the various assays, animals exposed to one apparatus on any given week were tested on another apparatus the following week; animals were exposed to any given apparatus only once every 3 weeks.
A 2 × 2 or 3 × 3 Latin-square design was used to assign subjects to an aCSFinjected and strychnine-or taurine-injected groups. For example, during the strychnine studies, animals were divided into two equivalent groups; each group was injected with either aCSF or strychnine (0.5 pmol or 167 pg) and subsequently exposed to a single behavioral apparatus on the first week of testing. On the second week, aCSF and strychnine 'groups' were switched, injected, and tested on a separate apparatus. This process was repeated until each animal had received both aCSF and drug injections and had been tested on each apparatus.
Taurine experiments were divided into two studies, for the first study, each animal received an aCSF, 50 pmol taurine (6.3 ng), or 1 nmol (125 ng) taurine microinjection. In the second study, each animal received aCSF or 5 pmol (0.6 ng) taurine. Again, injection order and exposure to each apparatus was counterbalanced across weeks such that animals receiving one type of injection and tested on a given apparatus 1 week would receive a different drug and behavioral assay the next week. We and others have previously shown that repeated microinjections into the same brain region does not substantially influence drug sensitivity even over several administrations (see [33, 42, 44] ). For all dependent variables examined, the values of aCSF-injected animals across the two experiments did not differ; and these groups were combined for further analysis.
For both the strychnine and taurine studies, there was a significant effect of previous apparatus exposure on the number of vertical-plane entries (rears) and the 'egress latency' in the light/dark box. These behaviors were therefore excluded from analysis. There were no trial-dependent effects for any plusmaze-dependent variable.
Drugs
Taurine (Tocris, Ellisville, MO) and strychnine-HCl (Sigma Aldrich, St. Louis, MO) were dissolved in artificial cerebrospinal fluid (120 mM NaCl, 4.5 mM KCl, 1 mM MgCl 2 , 26 mM NaHCO 3 , 1.2 mM NaH 2 PO 4 , 10 mM dglucose) that was vigorously bubbled with 95% O 2 /5% CO 2 for at least 15 min. The solutions were then sterile filtered (Millipore 0.2 m filters, Gellman) and used immediately for injection. For antagonist strychnine, 0.5 pmol (167 pg) was injected bilaterally. This dose should equate to a local concentration approaching 1 M near the tip of the injection cannula, a maximally efficacious concentration for strychnine-sensitive glycine receptors expressed by lateral/basolateral amygdala neurons [29] . Similarly, taurine doses of 5 pmol (0.6 ng), 50 pmol [36] ). Note the majority of guide cannulae appeared to terminate the anterior portions of the lateral nucleus.
(6.3 ng), or 1 nmol (125 ng) were injected bilaterally since these doses would approach 10 M, 0.1 mM, or 2 mM near the tip of the injection cannula. These concentrations represent the 'foot' and the 'maximum' of the taurine concentration-response curve that is specific for strychnine-sensitive glycine receptors expressed by the lateral/basolateral amygdala neurons [29] .
Histology
Following all behavioral assays, rats were given a lethal dose of sodium pentobarbital (90 mg/kg, IP) and, when deeply anesthetized, were transcardially perfused with buffered saline, followed by 10% formalin in saline. The brains were removed and stored in 10% formalin for at least 1 week before being sectioned on a freezing microtome (60 m sections), mounted onto slides, and stained with cresyl violet according to standard procedures. The location of the guide cannulae was determined using a light microscope. The approximate tip of the guide cannulae in each rat is shown in Fig. 1 .
Data analysis
All analyses and fits of data were performed using Prism 4.02 (GraphPad Software Inc., San Diego, CA). For Figs. 3-7, data were normalized to the mean values for aCSF-controls within a particular experiment and expressed as 'percent'. Where appropriate, dependent variables were analyzed using paired t-test/paired two-way ANOVA (strychnine) or standard between-group two-way ANOVA (taurine) according to established procedures [35] . Tests for normality were performed using the Shapiro-Wilk test [47] . P < 0.05 was considered significant in all cases.
Results
Strychnine microinjection into the amygdala reduces anxiety-like behavior
Consistent with previous results demonstrating that lateral/ basolateral amygdala neurons express functional strychnine-sensitive glycine receptors [12, 29, 30] , microinjection of strychnine (0.5 pmol or 167 pg) directly into this brain region reduced 'anxiety-like' behaviors in two separate assays. In the elevated plus maze (Table 1) , strychnine injected into the basolateral amygdala significantly decreased the amount of time rats (n = 20, two separate cohorts) spent in the closed arms (P < 0.05, paired t-test) and also tended to increase (P ∼ 0.1, paired t-test) open-arm time. However, strychnine did not substantially alter the number of open-arm entries or the total number of arm entries. Neither was the amount time animals spent in the junction between open and closed arms significantly affected by strychnine microinjection (not shown).
Because different assays of 'anxiety-like' behavior appear to measure distinct behavioral components [23] , we confirmed the apparent anxiolytic effects of strychnine using the light/dark box ( Table 1) . As in the plus maze, strychnine injected into the basolateral amygdala caused modest effects on anxiety-like behavior suggested by increased number of transitions between the light and dark compartments (P < 0.05, paired t-test) and the reduced latency to re-enter the light side following initial egress (P < 0.05, paired t-test). There was also a trend for strychnine to increase the amount of time spent in the light side of the apparatus (P ∼ 0.1, paired t-test). The time the rats spent moving in the apparatus (235.5 ± 3.7 s for aCSF versus 236.3 ± 3.2 s for strychnine) and the total number of moves made during the assay (75.5 ± 2.6 for aCSF versus 73.9 ± 2.3 for strychnine) were not significantly affected. Together, these findings indicate that strychnine, an antagonist of glycine receptors expressed in the basolateral amygdala, modulates anxiety-like behavior expressed in both the elevated plus maze as well as the light/dark box.
Taurine microinjection into the amygdala and anxiety-like behavior
In light of our findings with strychnine, we hoped to examine the effects of a glycine receptor agonist on anxiety-like behaviors. Because the amino acid glycine is also a co-agonist for the NMDA receptor [25] , we chose to inject taurine since this ␤-amino acid is a partial agonist with some efficacy at amygdala strychnine-sensitive glycine receptors [29] and does not posses any apparent co-agonist activity at the NMDA receptor [3, 32] . Taurine microinjections were performed across two separate experiments that utilized different doses. For experiment 1 (n = 12), we microinjected aCSF, 50 pmol (6.3 ng) taurine, and 1 nmol (125 ng) taurine while experiment 2 (n = 13) tested aCSF and 5 pmol (0.6 ng) taurine.
In the elevated plus maze, neither open-arm time, closed-arm time, nor open-arm entries were significantly different between experiments; aCSF-injection data was combined from the two different experiments. Regardless, data from both experiments demonstrated that taurine did not produce a dose-dependent effect on any plus-maze-dependent variables ( Table 2 ). In support of these findings, taurine microinjection into the amygdala also did not have any significant effects in the light dark box (Table 2 ). These findings suggest that the effects of taurine on anxiety-like behavior are negligible across this population of animals.
Rat behavior in the plus maze and light/dark box can be segregated into distinct phenotypic populations
During the analysis of the previous datasets, it was noted that the standard error associated with many of the 'anxiety'-specific dependent variables in the aCSF-injected animals did not decrease even after the addition of substantial numbers of rats to the study. This suggested to us that the data may not be normally distributed about a single mean. Indeed, the distribution of open-arm times from aCSF-injected rats on the plus maze was found not to be normal (W = 0.92, P < 0.01, n = 45 for strychnine and taurine studies). A plot of this distribution ( Fig. 2A) suggested that the data were consistent with two separate populations, animals that avoided the open arm (mean time of ∼30 s) and those with longer open-arm times (mean ∼120 s). The other plus-maze-dependent variables, including open-arm entries, closed-arm time, and junction time, appeared to be described as normal distributions (not shown).
These findings led us to examine the light/dark box distributions in aCSF-injected rats. There are several dependent variables in this assay that are believed to be measures of 'anxiety' in rodents, including total time spent in the light side, number of light/dark transitions, and time to re-enter the light side once the animal has made its initial egress into the dark. The light/dark transitions in aCSF-injected animals was normally distributed (W = 0.98, P 0.05) while the 're-entry latency' (time to re-enter the light side following initial egress into the dark) distribution was not (W = 0.68, P < 0.0001). In the latter case, the distribution appeared biased toward short latencies (<60 s) for the majority of animals (n = 36/45) with a small population (9/45) taking much longer (>120 s) to re-enter the light side (not shown). The light-side time distributions (Fig. 2B) were in contrast spread across a range and could be well fit by singlecomponent (R 2 = 0.68) or two-component (R 2 = 0.87 and 0.94 for each) Gaussian distributions. Together with the plus maze finding, our data suggest that aCSF-injected animals can be sub- divided into at least two populations possessing either high or low levels of anxiety-like behaviors.
'Phenotype' influences strychnine effects in the plus maze and light/dark box
We subsequently re-analyzed the plus maze and light/dark box data by first arbitrarily separating animals into groups based on their relative expression of anxiety-like behaviors. Fig. 2A) . 'Low' animals were so identified if their open-arm times were <90 s while 'high' animals were defined as having open-arm times ≥90 s. This time point represents the approximant gap between the two populations identified in Fig. 2A and generally divided each experimental group in two approximately equivalent populations. Two-way ANOVA analysis revealed a significant interaction between 'phenotype' and strychnine treatment for closed-arm time (F = 7.2, P < 0.05) and trend towards significance for open-arm time (F = 3.5, P = 0.08). A Bonferroni's post-test of this data indicated that strychnine significantly increased open-arm times (Fig. 3A , P < 0.05) and decreased closed-arm times ( (Fig. 3C ) nor open-arm entries (Fig. 3D) (Fig. 3D , F = 14.84, P < 0.01). These findings suggest that the segregation of animals based on open-arm times may in fact predict the efficacy of strychnine microinjection into the basolateral amygdala and that the population-effects of strychnine (Table 1) were due almost entirely to the drug's actions in 'low open-arm time' individuals.
For the light/dark box, data were segregated based on lightside times. However, since two distinct populations could not be reliably identified (Fig. 2B) , we used the mean light-side time for each experiment to divide animals into two groups, 'low light-side time' animals representing the half-population spending the least amount of time in the light side and 'high light-side time' individuals that spent more of their time in the light side. Two-way ANOVA across phenotype and strychnine treatment revealed a significant interaction between variables for light-side time (Fig. 4A , F = 10.6, P < 0.01). Bonferroni's posttests of these data indicate that strychnine injection significantly increased in light-side time in 'low light-side time' animals (P < 0.01) without affecting 'high light-side time' individuals. The number of transitions between the light and dark compartments, a measure of exploratory behavior, was significantly different between phenotypes (Fig. 4B , F = 11.6, P < 0.01). However, unlike the time spent in the light side, only the number of transitions of 'high light-side time' animals appeared to be influenced by strychnine microinjection (P < 0.05). Strychnine also significantly decreased the re-entry latency but only for the 'low light-side time' animals ( Fig. 4C , P < 0.05 with Bonferroni's post hoc). There was also a trend for the different phenotypes to differ in this particular dependent variable (F = 3.5, P ∼ 0.07). Move distance was not significantly altered by strychnine microinjection in either phenotype (Fig. 4D) . These findings indicate that strychnine microinjection into the lateral/basolateral amygdala specifically alters many of the variables ascribed to anxiety-like behavior. Like the plus maze data, the 'basal' (e.g. aCSF-injected) anxiety-like behavior of an animal may be associated with strychnine efficacy across several distinct light/dark box variables.
'Phenotype' also influences taurine efficacy in the plus maze but not the light/dark box
As with strychnine, we re-analyzed the taurine microinjection data by segregating animals based on their apparent 'basal' (aCSF) phenotype. In this context, there was a significant effect of both taurine dose and phenotype on open-arm time (Fig. 5A , F = 3.6, P < 0.05 for taurine effect and F = 10.8, P < 0.01 for phe- Fig. 4 . Injection of strychnine into the lateral/basolateral amygdala modulates anxiety-like behavior in the light/dark box. (A) There was a significant interaction between phenotype and strychnine microinjection relative to aCSF (P < 0.01, two-way repeated measures ANOVA) with strychnine ( ) significantly increasing the total amount time 'low light-side time' animals spent in this side of the apparatus (left; ** P < 0.01, Bonferroni's post-test). Strychnine microinjection did not influence this variable in 'high light-side time' individuals (right). (B) Strychnine significantly increased the number of transitions between light and dark compartments in the 'high light-side time' animals (P < 0.05 with Bonferroni's post-test) but not the 'low light-side time' individuals. The analysis also indicated a significant main-effect of phenotype ( § § P < 0.01, repeated measures two-way ANOVA). (C) Strychnine significantly reduced re-entry latency (the amount of time an animal takes to re-enter the light side of the apparatus following its initial egress to the dark side) in 'low light-side time' individuals (left; * P < 0.05, Bonferroni's post-test) but not the other phenotype (right). (D) Strychnine did not alter the total distance traveled during the test for either phenotype, suggesting the drug's effects on other parameters were not significantly influenced by locomotor-related behaviors. However, 'high light-side time' individuals traveled a greater distance than 'low light-side time' animals (P < 0.01 for phenotype).
notype, repeated-measures two-way ANOVA) with Bonferroni's post hoc analysis revealing a significant increase in open-arm time at the 50 pmol (6.3 ng) dose but only in 'low open-arm time' animals. This suggested an anxiolytic effect of taurine that was further supported by significant increases in the number of open-arm entries in these same animals (Fig. 5D , F = 4.9, P < 0.01 for an overall effect of taurine dose). Bonferroni's posttests of these open-arm entry data identified a significant increase for both the 50 pmol dose ( ** P < 0.01) in the 'low open-arm time' animals but not in the 'high open-arm time' phenotype. There was a trend for the 1 nmol (125 ng) taurine dose to produce similar effects on open-arm time and entries although this did not reach statistical significance. Similar non-significant trends were seen for decreased closed-arm time in the 'low' animals ( Fig. 5B) . Taurine did not substantially affect the total number of arm entries in either phenotype (not shown) nor did it modulate the amount of time animals spent in the junction between open and closed arms (Fig. 5C) . Together, these data suggest that microinjection of taurine into the lateral/basolateral amygdala can alter some dependent variables measured in the plus maze. In contrast to these data, taurine did not produce substantial effects for any variable measured in the in the light/dark box (Fig. 6 ).
Relationship between plus maze and light/dark box populations
Our data clearly suggest that ligands acting at BLA glycine receptors are most effective in animals exhibiting relatively high levels of anxiety-like behavior. However, the reduced efficacy of taurine relative to strychnine, particularly in the light/dark box, led us to examine whether individuals with high levels of anxiety-like behavior in one apparatus were the same individuals exhibiting similar behaviors in the other apparatus. Using aCSF data from animals in both the strychnine and taurine studies (n = 45), correlation analysis of light-side time in the light/dark box and open-arm time in the plus maze indicated a significant co-variation between these dependent variables (Spearman rank r S = 0.52 with a 95% confidence interval = 0.26-0.71; P < 0.001). However, these aCSF-injected animals spent 47.8 ± 4.4% of the time in the light side of the light/dark apparatus while spending only 21.4 ± 3.1% of their time on the open arms of the plus maze. Thus, while there is significant co-variation between these measures, these data also imply that anxiety-like behaviors, as measured by these dependent variables, are not as robustly expressed in the light/dark box compared with the plus maze.
To examine how well populations defined by one assay might predict drug sensitivity in the other assay, we performed a post hoc segregation of aCSF-injected animals based on their lightside times in the light-dark box (these are the 'low light-side time' and 'high light-side time' animals illustrated in Figs. [4] [5] [6] and then assessed the plus maze effects of BLA microinjection of strychnine and taurine in these specific individuals. This effectively examines drug sensitivity in animals that found both behavioral assays anxiogenic relative to the entire population. For strychnine-injected animals, there were significant main effects for strychnine (F = 6.0, P < 0.05) and for the interaction between strychnine and phenotype (F = 10.1, P < 0.01, two-way ANOVA). This was due exclusively to the increased amount of time 'low light-side time' individuals (n = 9) spent in the open arm of the plus maze following strychnine microinjection ( with main effects of strychnine (F = 8.8, P < 0.01) and interaction between phenotype and strychnine (F = 5.8, P < 0.05). Stychnine microinjection did not produce any effects on junction time (no shown), on the number of arm transitions (not shown), or on open-arm entries (Fig. 7B) regardless of phenotype.
Similar results were found with the taurine microinjection dataset. That is, there was a significant interaction between taurine and phenotype for light-side time (F = 3.7, P < 0.05). Post-tests indicated a significant increase in open-arm time in the light/dark-defined 'low light-side' individuals (Fig. 7C) at the highest dose of taurine tested (1 nmol or 125 ng; P < 0.05). Regardless of the population, neither closed-arm time (not shown) nor junction time (not shown) nor open-arm entries (Fig. 7D) were significantly influenced in a dose-dependent fashion by taurine microinjections into this brain region. Together, these data strongly suggest that the populations defined by anxiety-like behaviors expressed in the light-dark box are differentially sensitive to the apparent anxiolytic activity of BLA-administered strychnine and taurine when measured in the plus maze.
Discussion
There are several major findings associated with the current work. Most importantly, strychnine and, to some extent, taurine produce behavioral effects in both elevated plus maze and the light/dark box when microinjected into the lateral and basolateral amygdala. These data may suggest that the strychnine-sensitive glycine receptors identified using in vitro preparations of this brain region [12, 29] function to modulate anxiety-like behaviors in vivo. Previous work has shown that lateral/basolateral amygdala GABA A receptor activation, either directly with agonist [9] or indirectly with benzodiazepine agonist [51] , causes anxiolysis while inhibition with receptor antagonists cause anxiogenesis [44] . Given that both glycine and GABA A receptors are ligand-gated chloride channels, we initially hypothesized that glycine receptor activation by taurine would also produce anxiolytic effects while inhibition of these receptors by strychnine might produce anxiogenic effects if the receptors were active under the conditions of our behavioral assays. Since the current study demonstrates that the glycine receptor antagonist strychnine actually decreased the expres- sion of anxiety-like behavior, we must conclude that glycine and GABA A receptors expressed in the lateral/basolateral amygdala do not have similar neurophysiological roles despite their similar biophysical characteristics.
The similarities between the anti-anxiety profiles for the partial agonist taurine and the competitive antagonist strychnine were unexpected and deserve some discussion. One possible explanation would be that taurine and strychnine are targeting separate neurotransmitter systems. At highest dose used here, taurine (a ∼2 mM concentration equivalent) could theoretically activate a modest GABA A receptor-mediated current. This dose might therefore produce an initial decrease in neuronal activity and could reduce anxiety-like behavior as is seen with GABA A receptor agonists like muscimol [9] . Although we observed such an anxiolytic effect in our studies, the lower 50 pmol (6.3 ng) dose produced similar effects but would be expected to produce a 0.1 mM concentration equivalent near the injection site, well below that needed to activate either recombinant [15] or native [48] GABA A receptors. Thus, while we cannot conclusively exclude possible contributions by GABA A receptors, it would be difficult to imagine an exclusively GABAergic mechanism to explain our taurine data given the similar effects of 50 pmol (6.3 ng) and 1 nmol (125 ng) taurine. An alternative explanation might be that taurine is producing its behavioral effects through BLA strychnine-sensitive glycine receptors, but acting as an antagonist rather than partial agonist. In isolated lateral/basolateral amygdala neurons, taurine has only poorto-modest efficacy compared to glycine [29] . Notably, several studies on recombinant glycine receptors have suggested that taurine possesses both 'antagonist-like' and 'agonist-like' activity with the antagonist-interactions occurring at a greater relative potency [45, 49] . Although similar studies have not been performed on native receptors, the relatively potent, dose-dependent effect of taurine in the current study along with the behavioral similarities between taurine and strychnine microinjection into the BLA are both consistent with idea that taurine may be acting more like an antagonist at strychnine-sensitive glycine receptors, at least in 'anxious' animals.
One of the most surprising findings of the current study is that segregation of animal phenotypes appeared to influence the efficacy of each drug. Our post hoc segregation is nonethe-less consistent with the natural separation of behavioral phenotypes in both rodent and non-human primate studies of anxiety-like behavior. For example, the elevated plus maze can segregate Wistar rats into populations with distinct levels of anxiety-like behavior [6] . And, genetic polymorphisms in the serotonin transporter are associated with differential expression of anxiety-related behaviors in non-human primates [5] . There are also several examples of phenotype-specific effects of anxiolytic drugs. The neurosteroid dehydroepiandrosterone is more efficacious in rats exhibiting heightened 'behavioral despair' [38] . And, distinct inbred mouse strains that differ in their 'anxiety' phenotypes are differentially sensitive to the anxiolytic effects of diazepam [23] . Such 'population' sensitivity appears to also be common across species as well [27] . The differential sensitivity of the individual phenotypes to the actions of both strychnine and taurine may therefore have much broader implications for the role of ssGlyR in the adult rat forebrain.
Finally, there were test-specific effects of drugs that deserve additional consideration. While strychnine appeared to reduce anxiety-like behavior in both assays, the most apparent effects of taurine were anxiolytic in the plus maze but negligible in the light/dark box. If glycine receptor activation is indeed associated with increased anxiety-like behavior as was suggested by our strychnine findings, the differential effects of taurine in these assays may reflect the relative differences in glycine receptor activity in each assay. Of course, assay-dependent drug effects may also reflect distinct neurobiological contributions to anxiety-like behaviors expressed in each apparatus. Clearly, the plus maze and light/dark box share many characteristics. They are both perceived as unconditioned responses to naturally aversive environments; and, anxiety-like behaviors expressed in both assays are sensitive to many of the same pharmacological manipulations (reviewed in [2, 7, 41, 50] ). Despite these similarities, anxiety-like behavior is clearly multidimensional [40] ; and, the unique environments in each assay are likely to recruit unique neurobiological processes. This is perhaps best demonstrated by the unique pharmacological sensitivities of behaviors expressed in the plus maze and light/dark box that have been occasionally described. For example, benzodiazepine and serotonin-specific (e.g. 5HT1 A ) anxiolytics do not always present a consistent anxiolytic profile when tested in both assays [10, 24] . Thus, the test-specific effects of taurine may merely provide an additional demonstration of the complex and multidimensional character of anxiety.
In conclusion, the data presented here suggests that strychnine-and taurine-sensitive receptors expressed in the lateral/basolateral amygdala may help modulate anxiety-like behaviors in rodents. More importantly, the behavioral influence by these receptors appears to be specific for 'sensitive' individuals. These findings suggest that heightened anxiety-like states are associated with increased strychnine-sensitive receptor activity and thus increased sensitivity to their pharmacological manipulation.
